SIRT1 Activation by Resveratrol Alleviates Cardiac Dysfunction via Mitochondrial Regulation in Diabetic Cardiomyopathy Mice

Oxidative Medicine and Cellular Longevity

Volumn 2017, Issue , 2017, Pages

  Ma, Sai ^a,b   Feng, Jing ^c   Zhang, Ran ^b   Chen, Jiangwei ^a   Han, Dong ^a   Li, Xiang ^a   Yang, Bo ^b   Li, Xiujuan ^a   Fan, Miaomiao ^a   Li, Congye ^a   Tian, Zuhong ^a   Wang, Yabin ^b   Cao, Feng ^a,b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c JINLING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLATION; BIOSYNTHESIS; CELL DEATH; CHEMICAL ACTIVATION; CYTOLOGY; GLUCOSE; HEART; MAMMALS;

DEACETYLATION EFFECTS; DIABETIC CARDIOMYOPATHY; MITOCHONDRIAL BIOGENESIS; MITOCHONDRIAL TRANSCRIPTION FACTOR; NUCLEAR RESPIRATORY FACTORS; PATHOLOGICAL CHANGES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; THERAPEUTIC TARGETS;

RESVERATROL;

ESTROGEN RELATED RECEPTOR ALPHA; GLUCOSE; LENTIVIRUS VECTOR; MITOCHONDRIAL DNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; NUCLEAR RESPIRATORY FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; RESVERATROL; SHORT HAIRPIN RNA; SILENT INFORMATION REGULATOR 1; SILENT INFORMATION REGULATOR PROTEIN; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; ERRALPHA ESTROGEN-RELATED RECEPTOR; ESTROGEN RECEPTOR; MITOCHONDRIAL PROTEIN; SIRTUIN 1; STILBENE DERIVATIVE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DEACETYLATION; DIABETIC CARDIOMYOPATHY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; H9C2(2-1) CELL LINE; HEART DISEASE; HEART FUNCTION; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; INSULIN RESISTANCE; KNOCKOUT MOUSE; MITOCHONDRIAL BIOGENESIS; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; CELL LINE; DRUG EFFECT; HUMAN; METABOLISM; MITOCHONDRION; TRANSGENIC MOUSE;

DEACETYLATION; DISEASES; METABOLISM; NUCLEIC ACIDS; PATHOLOGY;

ANIMALS; CELL LINE; DIABETIC CARDIOMYOPATHIES; DNA-BINDING PROTEINS; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; NF-E2-RELATED FACTOR 1; RECEPTORS, ESTROGEN; SIRTUIN 1; STILBENES; TRANSCRIPTION FACTORS;

EID: 85028643934     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2017/4602715     Document Type: Article

References (58)

1. D. R. Whiting, L. Guariguata, C. Weil, and J. Shaw, "IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030," Diabetes Research and Clinical Practice, vol. 94, no. 3, pp. 311-321, 2011.
2. F. Liu, R. Song, Y. Feng et al., "Upregulation of MG53 induces diabetic cardiomyopathy through transcriptional activation of peroxisome proliferation-activated receptor α," Circulation, vol. 131, no. 9, pp. 795-804, 2015.
3. R. B. Devereux, M. J. Roman, M. Paranicas et al., "Impact of diabetes on cardiac structure and function: the strong heart study," Circulation, vol. 101, no. 19, pp. 2271-2276, 2000.
4. W. B. Kannel and D. L. McGee, "Diabetes and cardiovascular disease. The Framingham study," The Journal of the American Medical Association, vol. 241, no. 19, pp. 2035-2038, 1979.
5. P. K. Battiprolu, B. Hojayev, N. Jiang et al., "Metabolic stressinduced activation of FoxO1 triggers diabetic cardiomyopathy in mice," The Journal of Clinical Investigation, vol. 122, no. 3, pp. 1109-1118, 2012.
6. Z. V. Wang and J. A. Hill, "Diabetic cardiomyopathy: catabolism driving metabolism," Circulation, vol. 131, no. 9, pp. 771-773, 2015.
7. Y. Pan, Y. Wang, Y. Zhao et al., "Inhibition of JNK phosphorylation by a novel curcumin analog prevents high glucoseinduced inflammation and apoptosis in cardiomyocytes and the development of diabetic cardiomyopathy," Diabetes, vol. 63, no. 10, pp. 3497-3511, 2014.
8. M. M. Sung, S. M. Hamza, and J. R. Dyck, "Myocardial metabolism in diabetic cardiomyopathy: potential therapeutic targets," Antioxidants & Redox Signaling, vol. 22, no. 17, pp. 1606-1630, 2015.
9. J. Ren, L. Pulakat, A. Whaley-Connell, and J. R. Sowers, "Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease," Journal of Molecular Medicine, vol. 88, no. 10, pp. 993-1001, 2010.
10. J. D. Schilling, "The mitochondria in diabetic heart failure: from pathogenesis to therapeutic promise," Antioxidants & Redox Signaling, vol. 22, no. 17, pp. 1515-1526, 2015.
11. H. Kang, S. Oka, D. Y. Lee et al., "Sirt1 carboxyl-domain is an ATP-repressible domain that is transferrable to other proteins," Nature Communications, vol. 8, article 15560, 2017.
12. G. Blander and L. Guarente, "The Sir2 family of protein deacetylases," Annual Review of Biochemistry, vol. 73, no. 1, pp. 417-435, 2004.
13. M. Sulaiman, M. J. Matta, N. R. Sunderesan, M. P. Gupta, M. Periasamy, and M. Gupta, "Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy," American Journal of Physiology-Heart and Circulatory Physiology, vol. 298, no. 3, pp. H833-H843, 2010.
14. R. Guo, W. Liu, B. Liu, B. Zhang, W. Li, and Y. Xu, "SIRT1 suppresses cardiomyocyte apoptosis in diabetic cardiomyopathy: an insight into endoplasmic reticulum stress response mechanism," International Journal of Cardiology, vol. 191, pp. 36-45, 2015.
15. K. T. Howitz, K. J. Bitterman, H. Y. Cohen et al., "Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan," Nature, vol. 425, no. 6954, pp. 191-196, 2003.
16. M. Jang, L. Cai, G. O. Udeani et al., "Cancer chemopreventive activity of resveratrol, a natural product derived from grapes," Science, vol. 275, no. 5297, pp. 218-220, 1997.
17. D. Bonnefont-Rousselot, "Resveratrol and cardiovascular diseases," Nutrients, vol. 8, no. 5, 2016.
18. S. Das and D. K. Das, "Resveratrol: a therapeutic promise for cardiovascular diseases," Recent Patents on Cardiovascular Drug Discovery, vol. 2, no. 2, pp. 133-138, 2007.
19. J. A. Baur, Z. Ungvari, R. K. Minor, D. G. Le Couteur, and R. de Cabo, "Are sirtuins viable targets for improving healthspan and lifespan?" Nature Reviews Drug Discovery, vol. 11, no. 6, pp. 443-461, 2012.
20. L. Yu, Y. Tu, X. Jia et al., "Resveratrol protects against pulmonary arterial hypertension in rats via activation of silent information regulator 1," Cellular Physiology and Biochemistry, vol. 42, no. 1, pp. 55-67, 2017.
21. B. Liu, S. Ghosh, X. Yang et al., "Resveratrol rescues SIRT1-dependent adult stem cell decline and alleviates progeroid features in laminopathy-based progeria," Cell Metabolism, vol. 16, no. 6, pp. 738-750, 2012.
22. C. D. Côté, B. A. Rasmussen, F. A. Duca et al., "Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network," Nature Medicine, vol. 21, no. 5, pp. 498-505, 2015.
23. S. Ma, Z. Zhang, F. Yi et al., "Protective effects of lowfrequency magnetic fields on cardiomyocytes from ischemia reperfusion injury via ros and NO/ONOO-," Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 529173, 9 pages, 2013.
24. D. Wang, P. Luo, Y. Wang et al., "Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism," Diabetes, vol. 62, no. 5, pp. 1697-1708, 2013.
25. R. I. Hamby, S. Zoneraich, and L. Sherman, "Diabetic cardiomyopathy," The Journal of the American Medical Association, vol. 229, no. 13, pp. 1749-1754, 1974.
26. A. Rawshani, A. Rawshani, S. Franzén et al., "Mortality and cardiovascular disease in type 1 and type 2 diabetes," The New England Journal of Medicine, vol. 376, no. 15, pp. 1407-1418, 2017.
27. C. D. Malchoff, "Diagnosis and classification of diabetes mellitus," Diabetes Care, vol. 35, Supplement 1, pp. S64-S71, 2012.
28. E. J. Vazquez, J. M. Berthiaume, V. Kamath et al., "Mitochondrial complex I defect and increased fatty acid oxidation enhance protein lysine acetylation in the diabetic heart," Cardiovascular Research, vol. 107, no. 4, pp. 453-465, 2015.
29. S. Boudina and E. D. Abel, "Diabetic cardiomyopathy revisited," Circulation, vol. 115, no. 25, pp. 3213-3223, 2007.
30. C. Christoffersen, E. Bollano, M. L. Lindegaard et al., "Cardiac lipid accumulation associated with diastolic dysfunction in obese mice," Endocrinology, vol. 144, no. 8, pp. 3483-3490, 2003.
31. L. M. Semeniuk, A. J. Kryski, and D. L. Severson, "Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice," American Journal of Physiology Heart and Circulatory Physiology, vol. 283, no. 3, pp. H976-H982, 2002.
32. D. L. Severson, "Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes," Canadian Journal of Physiology and Pharmacology, vol. 82, no. 10, pp. 813-823, 2004.
33. V. Leko, B. Varnum-Finney, H. Li et al., "SIRT1 is dispensable for function of hematopoietic stem cells in adult mice," Blood, vol. 119, no. 8, pp. 1856-1860, 2012.
34. M. W. McBurney, X. Yang, K. Jardine et al., "The mammalian SIR2α protein has a role in embryogenesis and gametogenesis," Molecular and Cellular Biology, vol. 23, no. 1, pp. 38-54, 2003.
35. R. Kühn and R. M. Torres, "Transgenesis Techniques," in Cre/loxP Recombination System and Gene Targeting, Springer, Totowa, NJ, 2002.
36. J. A. Baur and D. A. Sinclair, "Therapeutic potential of resveratrol: the in vivo evidence," Nature Reviews Drug Discovery, vol. 5, no. 6, pp. 493-506, 2006.
37. S. Guo, Q. Yao, Z. Ke, H. Chen, J. Wu, and C. Liu, "Resveratrol attenuates high glucose-induced oxidative stress and cardiomyocyte apoptosis through AMPK," Molecular and Cellular Endocrinology, vol. 412, pp. 85-94, 2015.
38. J. P. Huang, S. S. Huang, J. Y. Deng, C. C. Chang, Y. J. Day, and L. M. Hung, "Insulin and resveratrol act synergistically, preventing cardiac dysfunction in diabetes, but the advantage of resveratrol in diabetics with acute heart attack is antagonized by insulin," Free Radical Biology and Medicine, vol. 49, no. 11, pp. 1710-1721, 2010.
39. P. K. Bagul, N. Deepthi, R. Sultana, and S. K. Banerjee, "Resveratrol ameliorates cardiac oxidative stress in diabetes through deacetylation of NFkB-p65 and histone 3," The Journal of Nutritional Biochemistry, vol. 26, no. 11, pp. 1298-1307, 2015.
40. G. Jia, V. G. DeMarco, and J. R. Sowers, "Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy," Nature Reviews Endocrinology, vol. 12, no. 3, pp. 144-153, 2016.
41. K. Huynh, B. C. Bernardo, M. M. JR, and R. H. Ritchie, "Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways," Pharmacology & Therapeutics, vol. 142, no. 3, pp. 375-415, 2014.
42. H. H. Zhang, X. J. Ma, L. N. Wu et al., "SIRT1 attenuates high glucose-induced insulin resistance via reducing mitochondrial dysfunction in skeletal muscle cells," Experimental Biology & Medicine, vol. 240, no. 5, 2015.
43. J. G. Duncan, "Mitochondrial dysfunction in diabetic cardiomyopathy," Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, vol. 1813, no. 7, pp. 1351-1359, 2011.
44. T. J. Regan, M. M. Lyons, S. S. Ahmed et al., "Evidence for cardiomyopathy in familial diabetes mellitus," Journal of Clinical Investigation, vol. 60, no. 4, p. 885, 1977.
45. E. R. Dabkowski, C. L. Williamson, V. C. Bukowski et al., "Diabetic cardiomyopathy-associated dysfunction in spatially distinct mitochondrial subpopulations," American Journal of Physiology-Heart and Circulatory Physiology, vol. 296, no. 2, pp. H359-H369, 2009.
46. C. A. Galloway and Y. Yoon, "Mitochondrial dynamics in diabetic cardiomyopathy," Antioxidants & Redox Signaling, vol. 22, no. 17, pp. 1545-1562, 2015.
47. R. Ni, D. Zheng, S. Xiong et al., "Mitochondrial calpain-1 disrupts ATP synthase and induces superoxide generation in type-1 diabetic hearts: a novel mechanism contributing to diabetic cardiomyopathy," Diabetes, vol. 65, no. 1, article db150963, pp. 255-268, 2015.
48. M. A. Aon and D. B. Foster, "Diabetic cardiomyopathy and the role of mitochondrial dysfunction: novel insights, mechanisms, and therapeutic strategies," Antioxidants & Redox Signaling, vol. 22, no. 17, pp. 1499-1501, 2015.
49. J. Lin, P. H. Wu, P. T. Tarr et al., "Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1α null mice," Cell, vol. 119, no. 1, pp. 121-135, 2004.
50. M. E. Patti, A. J. Butte, S. Crunkhorn et al., "Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1," Proceedings of the National Academy of Sciences, vol. 100, no. 14, pp. 8466-8471, 2003.
51. L. M. Sparks, H. Xie, R. A. Koza et al., "A high-fat diet coordinately downregulates genes required for mitochondrial oxidative phosphorylation in skeletal muscle," Diabetes, vol. 54, no. 7, pp. 1926-1933, 2005.
52. N. Gleyzer, K. Vercauteren, and R. C. Scarpulla, "Control of mitochondrial transcription specificity factors (TFB1M and TFB2M) by nuclear respiratory factors (NRF-1 and NRF-2) and PGC-1 family coactivators," Molecular and Cellular Biology, vol. 25, no. 4, pp. 1354-1366, 2005.
53. Z. Wu, P. Puigserver, U. Andersson et al., "Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1," Cell, vol. 98, no. 1, pp. 115-124, 1999.
54. R. Cartoni, B. Léger, M. B. Hock et al., "Mitofusins 1/2 and ERRα expression are increased in human skeletal muscle after physical exercise," The Journal of Physiology, vol. 567, no. 1, pp. 349-358, 2005.
55. J. M. Huss, K. Imahashi, C. R. Dufour et al., "The nuclear receptor ERRα is required for the bioenergetic and functional adaptation to cardiac pressure overload," Cell Metabolism, vol. 6, no. 1, pp. 25-37, 2007.
56. S. N. Schreiber, R. Emter, M. B. Hock et al., "The estrogenrelated receptor α (ERRα) functions in PPARγ coactivator 1α (PGC-1α)-induced mitochondrial biogenesis," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 17, pp. 6472-6477, 2004.
57. D. Kang, S. H. Kim, and N. Hamasaki, "Mitochondrial transcription factor A (TFAM): roles in maintenance of mtDNA and cellular functions," Mitochondrion, vol. 7, no. 1, pp. 39-44, 2007.
58. T. Chen, J. Li, J. Liu et al., "Activation of SIRT3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via the TGF-β/Smad3 pathway," American Journal of Physiology-Heart and Circulatory Physiology, vol. 308, no. 5, pp. H424-H434, 2015.